Property Name |
Property Value |
Unit |
Raw Value |
Raw Unit |
Annotation |
Factor |
Reference |
AUC |
30000.0 |
ng.h/ml |
30.0 |
mg.h/l |
Oral single dose; |
|
DRUGBANK |
Bioavailability |
63.0 |
% |
>63 |
% |
PO, oral; |
|
The Pharmacological Basis of Therapeutics |
C Max |
1000.0 |
ng/ml |
1.0 |
ug/ml |
Oral single dose; |
|
DRUGBANK |
C Max |
2000.0 |
ng/ml |
2.0 |
ug/ml |
Oral single dose; |
|
DRUGBANK |
C Max |
1200.0 |
ng/ml |
1.2 |
mcg/ml |
Oral single dose; adults; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
T Max |
2.5 |
h |
1-4 |
h |
Oral single dose; |
|
DRUGBANK |
T Max |
5.0 |
h |
2-8 |
h |
Oral single dose; |
|
DRUGBANK |
T Max |
2.0 |
h |
2.0 |
h |
Oral single dose; adults; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
Tss |
72.0 |
h |
3.0 |
day |
Oral multiple dose; |
|
DRUGBANK |
Metabolic |
65.0 |
% |
65 |
% |
|
|
DRUGBANK |
Metabolic |
25.0 |
% |
25 |
% |
|
|
DRUGBANK |
Clearance |
4.3 |
L/h |
51.7-91.3 |
ml/min |
|
|
DRUGBANK |
Clearance |
0.11 |
L/h/kg |
1.9±0.3 |
ml/min/kg |
|
Children ↑ ;RD, renal impairment, Renal disease,including uremia ↓ ;Cystic fibrosis ↑ ; |
The Pharmacological Basis of Therapeutics |
Clearance |
0.13 |
L/h/kg |
2.1 |
ml/min/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Volume of Distribution |
1.6 |
L/kg |
1.6±0.2 |
L/kg |
|
Neonates ↑ ;Children ↓ ;RD, renal impairment, Renal disease,including uremia → ;Cystic fibrosis → ; |
The Pharmacological Basis of Therapeutics |
Volume of Distribution |
1.5 |
L/kg |
1.5 |
L/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Half-life |
9.0 |
h |
8-10 |
h |
|
RD, renal impairment, Renal disease,including uremia ↑ ; |
DRUGBANK |
Half-life |
10.0 |
h |
10±2 |
h |
|
Children ↓ ;RD, renal impairment, Renal disease,including uremia ↑ ;Cystic fibrosis ↓ ;normal BMI → ; |
The Pharmacological Basis of Therapeutics |
Half-life |
9.6 |
h |
9.6 |
h |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Toxicity LD50 |
2764.0 |
mg/kg |
2764.0 |
mg/kg |
PO, oral; mouse; |
|
DRUGBANK |
Toxicity LD50 |
5300.0 |
mg/kg |
>5300 |
mg/kg |
PO, oral; Rattus, Rat; |
|
DRUGBANK |
Eliminate Route |
55.0 |
% |
50-60 |
% |
Urinary excretion; PO, oral; |
|
DRUGBANK |
Eliminate Route |
80.0 |
% |
~80 |
% |
Urinary excretion; Unchanged drug; |
|
DRUGBANK |
Eliminate Route |
63.0 |
% |
63±10 |
% |
Urinary excretion; Unchanged drug; |
Cystic fibrosis → ; |
The Pharmacological Basis of Therapeutics |
Protein Binding |
44.0 |
% |
44 |
% |
plasma proteins; |
|
DRUGBANK |
Protein Binding |
37.0 |
% |
37±5 |
% |
|
RD, renal impairment, Renal disease,including uremia → ;hypoalbuminemia Alb → ;Cystic fibrosis → ; |
The Pharmacological Basis of Therapeutics |